Dr. Haibo Lu 陆海波
Chief Physician
Medical Oncology (IV), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Neuroendocrine tumors and gastrointestinal cancers, including esophageal, gastric, liver, pancreatic, colorectal cancer and gastrointestinal stromal tumors. Treatments include chemotherapy, biological therapy, targeted therapy, and immunotherapy.
Dr. Lu graduated from Harbin Medical University in 1992, earning a master’s degree in 1997 and a PhD in oncology in 2006. A visiting scholar at a US cancer center in 2011, Dr. Lu has worked in medical oncology for nearly 33 years. Appointed chief physician in 2009 and professor in 2019, Dr. Lu serves as department head and supervisor for doctoral, master’s, and postdoctoral students.
Professional roles
- Standing Committee Member, Neuroendocrine Tumor Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Neuroendocrine Tumor Professional Committee, China Medical Promotion Association
- Chair, Neuroendocrine Tumor Professional Committee, Heilongjiang Medical Doctor Association
Name order: in Chinese the family name comes first (Lu Haibo). Papers usually list the name as Haibo Lu or Lu H.
Selected publications
34 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Acad Radiol, 2026 (senior author): Predicting Response to Somatostatin Analog Therapy in GEP-NET Liver Metastases: A Machine Learning Approach with ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT. PubMed 42760167
- Ecotoxicol Environ Saf, 2026 (senior author): CEBPB as a candidate mediator of DEGDB-induced tumor-associated phenotypes in colorectal cancer cells. PubMed 42617514
- Front Endocrinol (Lausanne), 2026 (senior author): (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: a systematic review and meta-analysis. PubMed 41798196
- J Inflamm Res, 2025 (senior author): Integration of Delta-Radiomics Features and Inflammatory Biomarkers for Neoadjuvant Chemo-Immunotherapy Efficacy in Locally Advanced Esophageal Squamous Cell Carcinoma. PubMed 41368348
- Int J Cancer, 2025 (senior author): The role of SPP1(+)TAMs in cancer: Impact on patient prognosis and future therapeutic targets. PubMed 40568964
- Front Endocrinol (Lausanne), 2025 (senior author): Clinical characteristics and survival outcomes of extrapulmonary neuroendocrine carcinomas: a retrospective study. PubMed 41220590
- Biomol Biomed, 2025 (senior author): Epidemiology, prognostic factors, and survival analysis in small cell esophageal carcinoma: A population-based study with external validation. PubMed 39226115
- Front Immunol, 2025 (senior author): Integrative analysis of semaphorins family genes in colorectal cancer: implications for prognosis and immunotherapy. PubMed 40103807
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion